Advertisement

Journal of Thrombosis and Thrombolysis

, Volume 4, Issue 3–4, pp 431–439 | Cite as

Platelet Glycoprotein IIb/IIIa Integrin Blockade in Coronary Artery Disease: Current State of the Art

  • Huay-Cheem Tan
  • Robert A. Harrington
  • James E. Tcheng
Article

Abstract

Platelets have been shown to play an important role in the pathogenesis of atherosclerosis, acute coronary syndromes, and ischemic complications after percutaneous coronary intervention. Fibrinogen binding via platelet surface glycoprotein (GP) IIb/IIIa receptors constitutes the "final pathway" in platelet aggregation leading to thrombus formation. The GP IIb/IIIa receptor inhibitors, a new class of antiplatelet agents that have emerged in recent years, show great promise in reducing complications of coronary angioplasty and acute coronary syndromes. This review will examine the biology of platelet GP IIb/IIIa receptors, the various classes of GP IIb/IIIa receptor antagonists, the results of the latest clinical trials, and their implications in current clinical practice.

glycoprotein IIb/IIa inhibition platelets coronary angioplasty 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fuster V, Badimon L, Badimon JJ, Chesebro J. The pathogenesis of coronary artery disease and the acute coronary syndromes. New Engl J Med 1992;326:242–250.Google Scholar
  2. 2.
    Ferguson JJ, Barasch E, Wilson JM, et al. Relation of clinical outcome to dissection and thrombus formation during coronary angioplasty. J Invasive Cardiol 1995;7:2–10.Google Scholar
  3. 3.
    Cowley MJ, Dorros G, Kelsey SF, Van Raden M, Detre KM. Acute coronary events associated with percutaneous transluminal coronary angioplasty. Am J Cardiol 1984;53:12C- 16C.Google Scholar
  4. 4.
    Detre KM, Holmes DR Jr, Holubkov R, et al. Incidence of periprocedural occlusion: The 1985-1986 National Heart, Lung and Blood Institute PTCA Registry. Circulation 1990; 82:739–750.Google Scholar
  5. 5.
    Lincoff AM, Popma JJ, Ellis SG, et al. Abrupt vessel closure complicating coronary angioplasty: Clinical, angiographic and therapeutic profile. J Am Coll Cardiol 1992;19:926–935.Google Scholar
  6. 6.
    Poncz M, Eisman R, Heidenreich R, et al. Structure of the platelet membrane glycoprotein IIb. J Biol Chem 1987;262: 8476–8482.Google Scholar
  7. 7.
    Plow EF, McEver RP, Coller BS, Woods VL Jr, Margurie GA, Ginsburg MH. Related binding mechanisms for fibrinogen, fibronectin, von Willebrand factor and thrombospondin on thrombin-stimulated human platelets. Blood 1985;66:724– 7Google Scholar
  8. 8.
    Gralnick HR, Williams SB, Coller BS. Fibrinogen competes with von Willebrand factor for binding to the glycoprotein IIb/IIIa complex when platelets are stimulated with thrombin. Blood 1984;64:797–800.Google Scholar
  9. 9.
    Phillips DR, Charo IF, Parisi LV, Fitzgerald LA. The platelet membrane glycoprotein IIb/IIIa complex. Blood 1988;71:831–843.Google Scholar
  10. 10.
    Chesebro JH, Lam JYT, Badimon L, Fuster V. Restenosis after arterial angioplasty: a hemorrheologic response to injury. Am J Cardiol 1987;60:10B-16B.Google Scholar
  11. 11.
    George JN, Caen JP, Nurden AT. Glanzmann thrombasthenia: The spectrum of clinical disease. Blood 1990;75:1383– 1395.Google Scholar
  12. 12.
    Coller BS. Interaction of normal, thrombasthenic, and Bernard-Soulier platelets with immobilized fibrinogen: Defective platelet-fibrinogen interaction in thrombasthenia. Blood 1980;55:169–178.Google Scholar
  13. 13.
    Coller BS. A new murine monoclonal antibody reports an activation dependent change in the conformation and/or microenvironment of the glycoprotein IIb/IIIa complex. J Clin Invest 1985;76:101–108.Google Scholar
  14. 14.
    Coller BS, Scudder LE, Beer J. Monoclonal antibodies to platelet glycoprotein IIb/IIIa receptor as antithrombotic agents. Ann NY Acad Sci 1991;614:193–213.Google Scholar
  15. 15.
    Coller BS, Folts JD, Scudder LE, Smith SR. Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model. Blood 1986;68:783–786.Google Scholar
  16. 16.
    Fitzgerald DJ, Hanson M, Fitzgerald GA. Systemic lysis protects against the effects of platelet activation during coronary thrombolysis. J Clin Invest 1991;88:1589–1595.Google Scholar
  17. 17.
    Gold HK, Coller BS, Yasuda T, Saito T, Fallon JT. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GP IIb/IIIa antibody in a canine preparation. Circulation 1988;77:670–677.Google Scholar
  18. 18.
    Yasuda T, Gold HK, Fallon JT, Leinbach RC, Guerrero JL. Monoclonal antibody against the platelet glycoprotein IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs. J Clin Invest 1988;81:1284–1291.Google Scholar
  19. 19.
    Tcheng JE, Ellis SG, George BS, Kereiakes DJ, Kleiman NS. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994;90:1757–1764.Google Scholar
  20. 20.
    Scarborough RM, Rose JW, Hsu MA, Phillips DR, Fried VA. Barbourin: A GP IIb/IIIa specific integrin antagonist from the venom of Sistrurus M barbouri. J Biol Chem 1991;266: 9359–9362.Google Scholar
  21. 21.
    Barker PL, Bullens S, Bunting S, Burdick DJ, Chan KS. Cyclic RGD peptide analogues as antiplatelet antithrombotics. J Med Chem 1992;35:2040–2048.Google Scholar
  22. 22.
    Steele PM, Chesebro JH, Stanson AW, et al. Balloon angioplasty: Natural history of the pathophysiological response to injury in a pig model. Circ Res 1985;57:105–112.Google Scholar
  23. 23.
    Kaplan AV, Leung LL-K, Leung WH, Grant GW, McDougall IR. Roles of thrombin and platelet membrane glycoprotein IIb/IIIa in platelet-subendothelial deposition after angioplasty in an ex vivo whole artery model. Circulation 1991;84: 1279–1288.Google Scholar
  24. 24.
    The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956– 961.Google Scholar
  25. 25.
    Lefkovits J, Ivanhoe R, Anderson K, Weisman H, Topol EJ, for the EPIC Investigators. Platelet IIb/IIIa receptor inhibition during PTCA for acute myocardial infarction: Insights from the EPIC Trial. Circulation 1994;90:I-564 (abstr).Google Scholar
  26. 26.
    Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months. Lancet 1994;343:881–886.Google Scholar
  27. 27.
    Aguirre FV, Topol EJ, Ferguson JJ, et al. Bleeding complications with the chimeric antibody to platelet GP IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. Circulation 1995;91:2882–2890.Google Scholar
  28. 28.
    Lincoff AM. EPILOG results. Presented at the 45th Annual Scientific Session of the American College of Cardiology, Orlando, Florida, March 24–27, 1996.Google Scholar
  29. 29.
    Ferguson JJ. EPILOG and CAPTURE Trials halted because of positive interim results. Circulation 1996;93:637.Google Scholar
  30. 30.
    Tcheng JE, Harrington RA, Kottke-Marchant K, et al. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin GP IIb/IIIa blocker integrelin in elective coronary intervention. Circulation 1995;91:2151– 2157.Google Scholar
  31. 31.
    Harrington RA, Kleiman NS, Kottke-Marchant K, et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide GP IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol 1995;76:1222–1227.Google Scholar
  32. 32.
    Tcheng JE, Lincoff AM, Sigmon KN, Kitt MM, Califf RM, Topol EJ, for the IMPACT-II Investigators. Platelet glycoprotein IIb/IIIa inhibition with integrilin™ during percutaneous coronary intervention: The IMPACT II Trial. Circulation 1995;92(Suppl I):I-543 (abstr).Google Scholar
  33. 33.
    Teirstein PS, Yakubov SJ, Thel MC, Wildermann N, Kereiakes DJ, et al. Platelet IIb/IIIa blockade with integrilin: atherectomy patients. J Am Coll Cardiol 1996;27: 334A (abstr).Google Scholar
  34. 34.
    Challapalli RM, Eisenberg MJ, Sigmon K, Leimberger J, for the EPIC Investigators. Platelet GP IIb/IIIa monoclonal antibody (c7E3) reduces distal embolization during percutaneous intervention of saphenous vein grafts. Circulation 1995;92:I-607 (abstr).Google Scholar
  35. 35.
    King SB. RESTORE results. Presented at the 45th Annual Scientific Session of the American College of Cardiology, Orlando, Florida, March 24–27, 1996.Google Scholar
  36. 36.
    Kleiman NS, Ohman EM, Califf RM, et al. Profound inhibi-tion of platelet aggregation with monoclonal antibody c7E3 Fab after thrombolytic therapy: Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 pilot study. J Am Coll Cardiol 1993;22:381–389.Google Scholar
  37. 37.
    Ohman EM, Kleiman NS, Gacioch G, et al., for the IMPACTAMI Investigators. Combined accelerated tissue-plasminogen activator and platelet GP IIb/IIIa integrin receptor blockade with Integrilin™ in acute myocardial infarction: Results of a randomized, placebo-controlled, dose-ranging trial. Circulation 1997;95:846–854.Google Scholar
  38. 38.
    Moliterno, Harrington RA, Califf RM. Randomized, placebo-controlled study of lamifiban with thrombolytic therapy for the treatment of acute myocardial infarction: Rationale and design for the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial In-farction (PARADIGM) Study. J Thromb Thrombol 1995;2: 165–169.Google Scholar
  39. 39.
    Simoons ML, de Boer MJ, van den Brand MJ, van Miltenburg J, Hoorntje JC. Randomized trial of a GP IIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation 1994;89:596603.Google Scholar
  40. 40.
    Schulman SP, Goldschmidt-Clermont PJ, Navetta FI, et al. Integrilin™ in unstable angina: A double-blind randomized trial. Circulation 1993;88:I-608 (abstr).Google Scholar
  41. 41.
    Crenshaw BS, Harrington RA, Tcheng JE. Novel antiplatelet agents: The glycoprotein IIb/IIIa inhibitors. Drugs 1995;4:1033–1044.Google Scholar
  42. 42.
    Berkowitz SD, Sane DC, Shavender JH, Sigmon KN, Topol EJ, Califf RM, for the EPIC Study Group. Analysis of the occurrence and clinical significance of thrombocytopenia with c7E3 (abciximab) in the EPIC Trial. J Am Coll Cardiol 1996;27:82A (abstr).Google Scholar
  43. 43.
    Faulds D, Sorkin EM. Abciximab (c7E3 Fab): A review of its pharmacology and therapeutic potential in ischemic heart disease. Drugs 1994;48:583–598.Google Scholar
  44. 44.
    Tcheng JE. Enhancing safety and outcomes with the newer antithrombotic and antiplatelet agents. Am Heart J 1995; 130:673–679.Google Scholar
  45. 45.
    Brezina K, Murphy M, Stonner T. Care of the patient receiving ReoPro after angioplasty. J Invas Cardiol 1994;6:38A- 42A.Google Scholar

Copyright information

© Kluwer Academic Publishers 1997

Authors and Affiliations

  • Huay-Cheem Tan
    • 1
  • Robert A. Harrington
    • 1
  • James E. Tcheng
    • 1
  1. 1.Division of Cardiology, Department of MedicineDuke University Medical CenterDurham

Personalised recommendations